<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30261931</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>28</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1471-2407</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>18</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>27</Day>                    </PubDate>                </JournalIssue>                <Title>BMC cancer</Title>                <ISOAbbreviation>BMC Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Data mining of digitized health records in a resource-constrained setting reveals that timely immunophenotyping is associated with improved breast cancer outcomes.</ArticleTitle>            <Pagination>                <MedlinePgn>933</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-018-4833-4</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Organizations that issue guidance on breast cancer recommend the use of immunohistochemistry (IHC) for providing appropriate and precise care. However, little focus has been directed to the identification of maximum allowable turnaround times for IHC, which is necessary given the diversity of hospital settings in the world. Much less effort has been committed to the development of digital tools that allow hospital administrators to monitor service utilization histories of their patients.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">In this retrospective cohort study, we reviewed electronic and paper medical records of all suspected breast cancer patients treated at one secondary-care hospital of the Mexican Institute of Social Security (IMSS), located in western Mexico. We then followed three years of medical history of those patients with IHC testing.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In 2014, there were 402 breast cancer patients, of which 30 (7.4% of total) were tested for some IHC biomarker (ER, PR, HER2). The subtyping allowed doctors to adjust (56.7%) or confirm (43.3%) the initial therapeutic regimen. The average turnaround time was 56 days. Opportune IHC testing was found to be beneficial when it was available before or during the first rounds of chemotherapy.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The use of data mining tools applied to health record data revealed that there is an association between timely immunohistochemistry and improved outcomes in breast cancer patients. Based on this finding, inclusion of turnaround time in clinical guidelines is recommended. As much of the health data in the country becomes digitized, our visualization tools allow a digital dashboard of the hospital service utilization histories.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>López-Pineda</LastName>                    <ForeName>Arturo</ForeName>                    <Initials>A</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-3409-1815</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Data Science, School of Medicine, Stanford University, 1265 Welch Road, Stanford, California, 94305, USA. arturolp@stanford.edu.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rodríguez-Moran</LastName>                    <ForeName>Mario F</ForeName>                    <Initials>MF</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-9790-1048</Identifier>                    <AffiliationInfo>                        <Affiliation>Facultad de Ciencias Médicas y Biológicas &quot;Dr. Ignacio Chávez&quot;, Universidad Michoacana de San Nicolás de Hidalgo, Av. Dr. Rafael Carrillo S/N, Esq. Dr. Salvador González Herrejón, Morelia, 58020, Michoacán, Mexico.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Álvarez-Aguilar</LastName>                    <ForeName>Cleto</ForeName>                    <Initials>C</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-1206-6659</Identifier>                    <AffiliationInfo>                        <Affiliation>Facultad de Ciencias Médicas y Biológicas &quot;Dr. Ignacio Chávez&quot;, Universidad Michoacana de San Nicolás de Hidalgo, Av. Dr. Rafael Carrillo S/N, Esq. Dr. Salvador González Herrejón, Morelia, 58020, Michoacán, Mexico.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Coordinación de Investigación en Salud, Delegación Michoacán, Instituto Mexicano del Seguro Social, Av. Madero Poniente No. 1200, Morelia, 58000, Michoacán, Mexico.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fuentes Valle</LastName>                    <ForeName>Sarah M</ForeName>                    <Initials>SM</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8571-9537</Identifier>                    <AffiliationInfo>                        <Affiliation>Hospital General Regional No. 1, Servicio de Ginecobstetricia, Instituto Mexicano del Seguro Social, Bosques de los Olivos No. 101, Charo, 61303, Michoacán, Mexico.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Acosta-Rosales</LastName>                    <ForeName>Román</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Delegación Michoacán, Instituto Mexicano del Seguro Social, Av. Madero Poniente No. 1200, Morelia, 58000, Michoacán, Mexico.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bhatt</LastName>                    <ForeName>Ami S</ForeName>                    <Initials>AS</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8099-2975</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Genetics, School of Medicine, Stanford University, 300 Pasteur Drive, Stanford, 94305, California, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medicine (Hematology), School of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, 94305, California, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sheth</LastName>                    <ForeName>Shruti N</ForeName>                    <Initials>SN</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medicine (Oncology), School of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, 94305, California, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bustamante</LastName>                    <ForeName>Carlos D</ForeName>                    <Initials>CD</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2884-4286</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Data Science, School of Medicine, Stanford University, 1265 Welch Road, Stanford, California, 94305, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Genetics, School of Medicine, Stanford University, 300 Pasteur Drive, Stanford, 94305, California, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>U01 HG007436-04</GrantID>                    <Agency>National Human Genome Research Institute</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>U01 FD004979</GrantID>                    <Agency>U.S. Food and Drug Administration</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>BMC Cancer</MedlineTA>            <NlmUniqueID>100967800</NlmUniqueID>            <ISSNLinking>1471-2407</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">Clinical coding</Keyword>            <Keyword MajorTopicYN="N">Data mining</Keyword>            <Keyword MajorTopicYN="N">Immunohistochemistry</Keyword>            <Keyword MajorTopicYN="N">Medical records</Keyword>            <Keyword MajorTopicYN="N">Mexico</Keyword>            <Keyword MajorTopicYN="N">Tumor biomarkers</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>25</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30261931</ArticleId>            <ArticleId IdType="doi">10.1186/s12885-018-4833-4</ArticleId>            <ArticleId IdType="pii">10.1186/s12885-018-4833-4</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>